Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cassava Sciences ( (SAVA) ) has issued an announcement.
On December 12, 2025, Cassava Sciences‘ Board of Directors approved cash bonus awards for its executives in recognition of their significant contributions in 2025. The company achieved progress on performance measures, including exploring the use of its drug simufilam in Tuberous Sclerosis Complex-related epilepsy, building a specialized team, and managing budgets effectively to support these objectives.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences operates in the biotechnology industry, with a focus on innovative treatments for neurological disorders. The company aims to develop transformative advancements in healthcare, particularly through its work with simufilam, a potential therapeutic for conditions like Alzheimer’s disease and epilepsy.
Average Trading Volume: 2,804,434
Technical Sentiment Signal: Sell
Current Market Cap: $141.5M
See more insights into SAVA stock on TipRanks’ Stock Analysis page.